Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer.

Phase 3 clinical trials of perioperative immunotherapy for resectable non-small cell lung cancer (NSCLC): In recent years, immunotherapy for NSCLC is not only limited to advanced disease, but also has shown gratifying efficacy for early resectable NSCLC. With the publication of the results of several phase 3 clinical trials, perioperative immunotherapy will become one of the main treatment modalities for resectable NSCLC. © 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

Citation

Zhijun Yuan, Mengyuan Yang, Xian Zhong. Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer. MedComm. 2024 Mar;5(3):e498

PMID: 38420164

search → result